ANTX

AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

AN2 Therapeutics, Inc. (ANTX) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Growth (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C-
Factor Score 2.0 / 5.0
Profitability
B-
Factor Score 2.9 / 5.0
Momentum
C
Factor Score 2.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -5.8
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -25.1%
Price Return 12M 295.6%
Catalyst Signal 0.00
Market Cap $169.6M
TTM Revenue N/A
Price / Sales N/A
ROE -51.3%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.5) C- (2.0) B- (2.9) C (2.3) C+ (2.6) C (2.5)
2026-11-10 C+ (2.5) C- (2.0) B- (2.9) C+ (2.5) C+ (2.6) C+ (2.5)
2026-11-03 C+ (2.5) C- (2.0) B- (2.9) B- (2.9) C+ (2.7) C+ (2.6)
2026-10-27 C+ (2.5) C- (1.9) B- (3.0) C+ (2.6) C+ (2.6) C+ (2.5)
2026-10-20 C+ (2.5) C- (1.9) B- (3.0) B- (3.0) C+ (2.6) C+ (2.6)
Page 1 of 4